Trial Profile
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study To Assess The Safety, Tolerability, And Pharmacokinetics Of Single Escalating Oral Doses Of PF-06427878 Co-Administered With Meal In Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Mar 2015
Price :
$35
*
At a glance
- Drugs PF 6427878 (Primary)
- Indications Hyperlipidaemia
- Focus Adverse reactions
- Sponsors Pfizer
- 03 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Dec 2014 Planned End Date changed from 1 Nov 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 11 Dec 2014 Planned primary completion date changed from 1 Nov 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.